임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 16-03-13 23:36
논문번호 92
논문제목(영문) Two-year clinical outcome after abciximab-coated stent implantation in patients with coronary artery disease.
국내외구분 국외 SCI여부 SCI(E)
연구책임자역할 교신저자
주저자명 Kim SS
교신저자명 Jeong MH
공동저자명 Kim SS, Hong YJ, Jeong MH, Kim W, Kim HK, Ko JS, Lee MG, Sim DS, Park KH, Yoon NS, Yoon HJ, Kim KH, Park HW, Kim JH, Ahn Y, Cho JG, Park JC, Song SJ, Cho DL, Kang JC;
게제년월일 2009-11-26
ISSN 1346-9843
Impact Factor 4.463
학술지명 Circulation journal
서지사항 0집 / 74권 / 3호,   페이지(442 - 448)
요약초록문
(Abstract) 입력		 BACKGROUND:
Despite abciximab-coated stents having an inhibitory effect on coronary artery restenosis, the medium-term clinical outcome is unknown.
METHODS AND RESULTS:
This prospective, randomized study compared the effects of the abciximab-coated stent, which was implanted in 95 patients, with those of control bare metal stents (BMS) implanted in 93 patients for de novo coronary lesions. Stent implantation was performed without any complications associated with the procedure. The 6-month intravascular ultrasound analysis showed that the area of neointimal hyperplasia was significantly smaller in the abciximab-coated stent group compared with the control stent group (+2.0+/-1.6 mm(2) vs +3.4+/-1.7 mm(2), P=0.001). However, at 2-year clinical follow up, there were no statistically significant differences in the incidences of total major adverse cardiac events (16% vs 24%, P=0.19) and cardiac death (0% vs 1.1%, P=0.3), target vessel revascularization (16% vs 21%, P=0.4) or non-fatal myocardial infarction (0% vs 2.3%, P=0.16) in the abciximab-coated stent group compared with the control stent group.
CONCLUSIONS:
Although abciximab-coated stents are safe and inhibit neointimal hyperplasia, they have no superiority over BMS in 2-year clinical outcome.
파일  C92+Circ+J.+2010;74(3)442-448..pdf (649.5K) DATE : 2021-05-25 13:11:15